Sanofi: FDA Approval of Dupixent Is Credit Positive for Sanofi
CORPORATES ISSUER COMMENT 30 March 2017 Contacts Knut Slatten 33-1-5330-1077 VP-Senior Analyst [email protected] Marina Albo 44-20-7772-5365 Managing Director [email protected] Sanofi FDA Approval of Dupixent Is Credit Positive for Sanofi On 28 March, the US Food and Drug Administration (FDA) approved Dupixent for the treatment of moderate-to-severe atopic dermatitis (AD), a severe formSanofi-Aventis Pakistan is engaged in the manufacture and sale of agricultural pesticides, pharmaceutical products and general and speciality chemicals. In addition, Co. acts as an indenting agent for a variety of products for its associates and certain other companies. Agricultural products include pesticides such as Aflix® for cotton crops, and Arelon® and Illoxan® for weeds. Pharmaceutical products include Avil®, Novalgin®, Surgam®, Idarac®, Daonil®, Lasix®, Tarivid®, Lasoride®, Trental®, and Haemaccel®, a blood plasma substitute. Chemical products include chemicals for the textile and leather industries such as Trevira CS® and products for the paint and glue industries.
Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:
- 130 countries
11,000 corporate issuers
21,000 public finance issuers
76,000 structured finance obligations
Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.
Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.